PAH News

November 8, 2018November 8, 2018

Transgelin Protein May Provide Clues on PAH Progression in Congenital Heart Disease, Study Says

News, PAH News

Transgelin, a smooth muscle protein, is abundant in patients with irreversible pulmonary arterial hypertension (PAH) secondary to congenital heart disease and may contribute to PAH progression, a study reports. The study, ... Read more

November 2, 2018November 9, 2018

Liquidia Completes Enrollment for Safety Portion of Phase 3 Trial on LIQ861 for PAH

News, PAH News

Liquidia Technologies has completed the enrollment for the safety part of a Phase 3 trial evaluating the safety and tolerability of LIQ861, an inhaled dry power formulation of treprostinil for the ... Read more

October 31, 2018November 6, 2018

Ventavis Shows Limited Ability to Improve Long-term Survival Rates in PAH Patients, Real-World Data Suggests

News, PAH News

Treatment with inhaled Ventavis (iloprost) has limited effectiveness in improving the survival rate of patients with pulmonary arterial hypertension (PAH), despite the clinical improvements it induces, real-world data suggests. ... Read more

October 16, 2018October 18, 2018

Data from PHAROS Trial Reveals Danger of Poorer Outcomes for Scleroderma Patients At-Risk of PH

News, PAH News, PH News

Patients with systemic sclerosis (SSc) at risk of having pulmonary hypertension (PH) also have similar risk factors for a poorer outcome as patients with SSc-PH and SSc-pulmonary arterial hypertension ... Read more

October 11, 2018October 11, 2018

Bellerophon’s Clinical Trials for INOpulse PH Therapies Moving Forward

News, PAH News, PH News

Bellerophon Therapeutics has announced positive data from its Phase 3 clinical trial investigating INOpulse in patients with pulmonary arterial hypertension (PAH), as well as the enrollment of the first group ... Read more

October 4, 2018October 11, 2018

Long-term Benefits of Ralinepag for PAH Patients Shown in Interim Data from Phase 2 Extension Trial

News, PAH News

Long-term use of ralinepag, an investigational therapy being developed by Arena Pharmaceuticals, can promote positive changes in the outcome of patients with pulmonary arterial hypertension (PAH), interim data from a Phase ... Read more

September 26, 2018September 28, 2018

Long-term Oxygen Therapy May Not Be Good for Idiopathic PAH, Rat Study Suggests

News, PAH News

Long-term oxygen therapy had a damaging effect on rats with induced idiopathic pulmonary arterial hypertension (PAH), leading to poorer outcomes and reduced survival rates. That finding was reported in the ... Read more

September 24, 2018September 25, 2018

PAH Treatments Fail to Benefit Patients with PH due to Left Heart Disease, Study Suggests

News, PAH News, PH News

Off-label use of pulmonary arterial hypertension (PAH) medications to treat patients with pulmonary hypertension caused by left heart disease (PH-LHD) is common, despite a lack of supporting clinical data. ... Read more

September 21, 2018September 26, 2018

Exhaled Breath Temperature Can be Potential Biomarker in Patients with Pulmonary Hypertension

News, PAH News, PH News

Exhaled breath temperature could serve as a potential prognostic biomarker for patients with pulmonary hypertension (PH), a new study shows. The study, “Exhaled Nitric Oxide and Exhaled Breath Temperature ... Read more

September 20, 2018September 20, 2018

Adempas Seen to Benefit Idiopathic PAH Patients Who Fail to Respond to Revatio in Pilot Study

News, PAH News

Idiopathic pulmonary arterial hypertension (IPAH) patients who failed to respond to treatment with Revatio (sildenafil), either alone or combined with other phosphodiesterase type 5 inhibitors, may benefit by switching to Adempas (riociguat), according to ... Read more

Pin It on Pinterest